Eversept Partners, LP Bicycle Therapeutics PLC Transaction History
Eversept Partners, LP
- $993 Million
- Q2 2025
A detailed history of Eversept Partners, LP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Eversept Partners, LP holds 211,469 shares of BCYC stock, worth $1.73 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
211,469Holding current value
$1.73 Million% of portfolio
0.15%Shares
1 transactions
Others Institutions Holding BCYC
# of Institutions
118Shares Held
42.1MCall Options Held
111KPut Options Held
16.6K-
Baker Bros. Advisors LP New York, NY10.9MShares$88.8 Million0.77% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.45MShares$28.2 Million6.5% of portfolio
-
Armistice Capital, LLC New York, NY2.8MShares$22.8 Million0.34% of portfolio
-
Westfield Capital Management CO LP Boston, MA2.66MShares$21.7 Million0.12% of portfolio
-
Siren, L.L.C. New York, NY2.01MShares$16.4 Million0.72% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $242M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...